CIK 0002100782 · <br>Emerging growth company
Generate Biomedicines, Inc.
Sign in to watch- Ticker
- GENB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831630228
- Phone
- 888-469-0055
- Business address
- 101 SOUTH STREET, SUITE 900, SOMERVILLE, MA, 02143
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $200,735
- in 2 filings, $201K under 10b5-1 plans
Net −$200,735. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion · Series B Preferred Stock | −2,953,586 | 0 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion · Series B Preferred Stock | −2,109,704 | 0 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion · Series C Preferred Stock | −2,531,644 | 0 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion · Series C Preferred Stock | −1,265,822 | 0 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion · Series C Preferred Stock | −2,109,704 | 0 | ||
| 2026-03-02 | Nally Michael Chief Executive Officer | Conversion | +658,327 | 1,316,654 | ||
| 2026-03-02 | Nally Michael Chief Executive Officer | Conversion · Series A Preferred Stock | −1,000,000 | 0 | ||
| 2026-03-02 | Bancel Stephane Director | Conversion | +724,160 | 724,160 | ||
| 2026-03-02 | Bancel Stephane Director | Conversion · Series A Preferred Stock | −1,100,000 | 0 | ||
| 2026-03-02 | Mendillo Jane L Director | Purchase | +1,500 | $16.00 | $24K | 1,500 |
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion | +12,723,940 | 12,723,940 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion | +13,702,224 | 13,702,224 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion | +987,491 | 987,491 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion | +2,777,752 | 2,777,752 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion | +2,777,752 | 2,777,752 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Purchase | +1,562,500 | $16.00 | $25.0M | 15,264,724 |
| 2026-03-02 | AFEYAN NOUBAR Director | Purchase | +1,562,500 | $16.00 | $25.0M | 4,340,252 |
| 2026-03-02 | AFEYAN NOUBAR Director | Purchase | +1,562,500 | $16.00 | $25.0M | 1,562,500 |
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion · Series A Preferred Stock | −18,483,785 | 0 | ||
| 2026-03-02 | AFEYAN NOUBAR Director | Conversion · Series A Preferred Stock | −17,016,215 | 0 |
Page 2 of 4 · 66 trades